Nivolumab in treatment of relapsed Hodgkin lymphoma

Abstract

The incidence of Hodgkin lymphoma (HL) relapses is 8-30 % and depend on disease stage, presence of unfavorable prognostic factors and treatment programme. Modern second-line treatment programmes are based on gemcitabine and carboplatin with following autologous stem cell transplantation and can reach many-year overall survival in 70 % of patients. For increasing treatment efficacy of relapsed HL monoclonal antibodies (brentuximab vedotin) and checkpoint inhibitors (nivolumab) are supplemented. Nowadays it makes an assessment of immunochemotherapy efficacy in patients with relapsed HL, determines long-term effects of treatment. Nevertheless, preliminary results allow to find a significant therapeutic advantages of immunochemotherapy with following autologous stem cell transplantation above standard polychemotherapy.